David F Ransohoff1. 1. UNC-CH, Chapel Hill, NC 27599, USA. ransohof@med.unc.edu
Abstract
BACKGROUND: "Discovery" research about molecular markers for diagnosis, prognosis, or prediction of response to therapy has frequently produced results that were not reproducible in subsequent studies. What are the reasons, and can observational cohorts be cultivated to provide strong and reliable answers to those questions? Experimental METHODS: Selected examples are used to illustrate: (i) what features of research design provide strength and reliability in observational studies about markers of diagnosis, prognosis, and response to therapy? (ii) How can those design features be cultivated in existing observational cohorts, for example, within randomized controlled clinical trial (RCT), other existing observational research studies, or practice settings like health maintenance organization (HMOs)? RESULTS: Examples include a study of RNA expression profiles of tumor tissue to predict prognosis of breast cancer, a study of serum proteomics profiles to diagnose ovarian cancer, and a study of stool-based DNA assays to screen for colon cancer. Strengths and weaknesses of observational study design features are discussed, along with lessons about how features that help assure strength might be "cultivated" in the future. CONCLUSIONS AND IMPACT: By considering these examples and others, it may be possible to develop a process of "cultivating cohorts" in ongoing RCTs, observational cohort studies, and practice settings like HMOs that have strong features of study design. Such an effort could produce sources of data and specimens to reliably answer questions about the use of molecular markers in diagnosis, prognosis, and response to therapy.
BACKGROUND: "Discovery" research about molecular markers for diagnosis, prognosis, or prediction of response to therapy has frequently produced results that were not reproducible in subsequent studies. What are the reasons, and can observational cohorts be cultivated to provide strong and reliable answers to those questions? Experimental METHODS: Selected examples are used to illustrate: (i) what features of research design provide strength and reliability in observational studies about markers of diagnosis, prognosis, and response to therapy? (ii) How can those design features be cultivated in existing observational cohorts, for example, within randomized controlled clinical trial (RCT), other existing observational research studies, or practice settings like health maintenance organization (HMOs)? RESULTS: Examples include a study of RNA expression profiles of tumor tissue to predict prognosis of breast cancer, a study of serum proteomics profiles to diagnose ovarian cancer, and a study of stool-based DNA assays to screen for colon cancer. Strengths and weaknesses of observational study design features are discussed, along with lessons about how features that help assure strength might be "cultivated" in the future. CONCLUSIONS AND IMPACT: By considering these examples and others, it may be possible to develop a process of "cultivating cohorts" in ongoing RCTs, observational cohort studies, and practice settings like HMOs that have strong features of study design. Such an effort could produce sources of data and specimens to reliably answer questions about the use of molecular markers in diagnosis, prognosis, and response to therapy.
Authors: Thomas F Imperiale; David F Ransohoff; Steven H Itzkowitz; Barry A Turnbull; Michael E Ross Journal: N Engl J Med Date: 2004-12-23 Impact factor: 91.245
Authors: Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark Journal: N Engl J Med Date: 2004-12-10 Impact factor: 91.245
Authors: Claire S Zhu; Paul F Pinsky; Daniel W Cramer; David F Ransohoff; Patricia Hartge; Ruth M Pfeiffer; Nicole Urban; Gil Mor; Robert C Bast; Lee E Moore; Anna E Lokshin; Martin W McIntosh; Steven J Skates; Allison Vitonis; Zhen Zhang; David C Ward; James T Symanowski; Aleksey Lomakin; Eric T Fung; Patrick M Sluss; Nathalie Scholler; Karen H Lu; Adele M Marrangoni; Christos Patriotis; Sudhir Srivastava; Saundra S Buys; Christine D Berg Journal: Cancer Prev Res (Phila) Date: 2011-03
Authors: Emanuel F Petricoin; Ali M Ardekani; Ben A Hitt; Peter J Levine; Vincent A Fusaro; Seth M Steinberg; Gordon B Mills; Charles Simone; David A Fishman; Elise C Kohn; Lance A Liotta Journal: Lancet Date: 2002-02-16 Impact factor: 79.321
Authors: Muin J Khoury; Tram Kim Lam; John P A Ioannidis; Patricia Hartge; Margaret R Spitz; Julie E Buring; Stephen J Chanock; Robert T Croyle; Katrina A Goddard; Geoffrey S Ginsburg; Zdenko Herceg; Robert A Hiatt; Robert N Hoover; David J Hunter; Barnet S Kramer; Michael S Lauer; Jeffrey A Meyerhardt; Olufunmilayo I Olopade; Julie R Palmer; Thomas A Sellers; Daniela Seminara; David F Ransohoff; Timothy R Rebbeck; Georgia Tourassi; Deborah M Winn; Ann Zauber; Sheri D Schully Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-03-05 Impact factor: 4.254
Authors: Beate Pesch; Dirk Taeger; Georg Johnen; Katarzyna Gawrych; Nadine Bonberg; Christian Schwentner; Harald Wellhäusser; Matthias Kluckert; Gabriele Leng; Michael Nasterlack; Yair Lotan; Arnulf Stenzl; Thomas Brüning Journal: Int Arch Occup Environ Health Date: 2013-10-16 Impact factor: 3.015
Authors: Sheri D Schully; Danielle M Carrick; Leah E Mechanic; Sudhir Srivastava; Garnet L Anderson; John A Baron; Christine D Berg; Jennifer Cullen; Eleftherios P Diamandis; V Paul Doria-Rose; Katrina A B Goddard; Susan E Hankinson; Lawrence H Kushi; Eric B Larson; Lisa M McShane; Richard L Schilsky; Steven Shak; Steven J Skates; Nicole Urban; Barnett S Kramer; Muin J Khoury; David F Ransohoff Journal: J Natl Cancer Inst Date: 2015-02-16 Impact factor: 13.506
Authors: Muin J Khoury; Tram Kim Lam; John P A Ioannidis; Patricia Hartge; Margaret R Spitz; Julie E Buring; Stephen J Chanock; Robert T Croyle; Katrina A Goddard; Geoffrey S Ginsburg; Zdenko Herceg; Robert A Hiatt; Robert N Hoover; David J Hunter; Barnet S Kramer; Michael S Lauer; Jeffrey A Meyerhardt; Olufunmilayo I Olopade; Julie R Palmer; Thomas A Sellers; Daniela Seminara; David F Ransohoff; Timothy R Rebbeck; Georgia Tourassi; Deborah M Winn; Ann Zauber; Sheri D Schully Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-03-05 Impact factor: 4.254
Authors: Nigel T Brockton; Stephanie J Gill; Stephanie L Laborge; Alexander H G Paterson; Linda S Cook; Hans J Vogel; Carrie S Shemanko; David A Hanley; Anthony M Magliocco; Christine M Friedenreich Journal: BMC Cancer Date: 2015-07-10 Impact factor: 4.430